Suppliers and packagers for AQVESME

AQVESME

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-205-05	4 BLISTER PACK in 1 CARTON (71334-205-05) / 14 TABLET, FILM COATED in 1 BLISTER PACK (71334-205-14)	2022-02-18
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-210-20	4 BLISTER PACK in 1 CARTON (71334-210-20) / 14 TABLET, FILM COATED in 1 BLISTER PACK (71334-210-14)	2022-02-18
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-215-50	4 BLISTER PACK in 1 CARTON (71334-215-50) / 14 TABLET, FILM COATED in 1 BLISTER PACK (71334-215-14)	2022-02-18
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-220-11	1 BLISTER PACK in 1 CARTON (71334-220-11) / 7 TABLET, FILM COATED in 1 BLISTER PACK	2022-02-18
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-225-12	1 KIT in 1 CARTON (71334-225-12) * 7 TABLET, FILM COATED in 1 BLISTER PACK (71334-205-07) * 7 TABLET, FILM COATED in 1 BLISTER PACK (71334-210-07)	2022-02-18
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-230-13	1 KIT in 1 CARTON (71334-230-13) * 7 TABLET, FILM COATED in 1 BLISTER PACK (71334-215-07) * 7 TABLET, FILM COATED in 1 BLISTER PACK (71334-210-07)	2022-02-18

AQVESME: Who Supplies It?

Last updated: May 2, 2026

AQVESME is not a uniquely identifiable pharmaceutical product name based on the information provided. Without the drug’s active ingredient (INN/USAN), dosage form (tablet, injection, etc.), strength, and country/market labeling, the supplier chain cannot be determined in a way that is complete and decision-grade.

Can suppliers for “AQVESME” be identified precisely?

No. “AQVESME” is an incomplete identifier for supplier mapping. Supplier lists for pharma products depend on the exact branded product configuration and the underlying API and manufacturing/packaging sites. With only the brand-like term, neither:

• API suppliers (raw material grade, polymorph/process routes, and DMF linkage) nor
• Finished dosage manufacturers (CMO/CDMO) nor
• Marketing authorization holders and distribution partners

can be tied to a single product record.

What supplier categories would be required to map AQVESME supply?

To identify suppliers for a specific branded pharma product, the supplier map must be anchored to verifiable identifiers, typically:

• Marketing authorization holder (MAH) for the relevant jurisdiction
• API manufacturer(s) linked to the product’s DMF/CEP filings (when applicable)
• Finished dose manufacturer(s) (tableting/filling/finishing) and packaging site(s)
• Clinical supply manufacturer (if the product is still in trials)
• Raw material excipient suppliers (only for detailed CMC supply-chain analysis)

No such jurisdictional and product-identifying attributes are provided for AQVESME.

What can be concluded from the name alone?

Only that “AQVESME” cannot be resolved to a unique supplier set without the underlying product identifiers that connect it to regulatory filings, labels, and manufacturing authorizations.

Key Takeaways

• “AQVESME” alone is not sufficient to produce an accurate supplier list.
• Supplier identification in pharma requires anchoring to the exact product record (API + dosage form + strength + jurisdiction/labeling).
• A decision-grade supplier map cannot be generated from the provided information.

FAQs

1. What information is required to identify pharma suppliers for a brand name?
   Active ingredient (INN/USAN), dosage form, strength, and jurisdiction/market authorization record.

2. Why can’t suppliers be inferred from a brand name only?
   Brands can map to multiple strengths, dosage forms, manufacturing sites, and jurisdictions, and names are often not unique.

3. What supplier types matter most for R&D or investment diligence?
   MAH, API manufacturer(s), finished dose manufacturer(s), and packaging/labeling sites linked to regulatory filings.

4. Can suppliers differ across countries for the same brand?
   Yes. Manufacturing and packaging networks are frequently jurisdiction-specific.

5. Does “supplier” mean API or finished product manufacturer?
   In pharma due diligence it means both, plus MAH and sometimes distribution roles, depending on the use case.

References

[1]